Introduction
============

Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer mortality worldwide ([@b1-ol-0-0-6736]). The most common type of gastric cancer is adenocarcinoma, which is classified into intestinal and diffuse types ([@b2-ol-0-0-6736]), which develop through distinct pathways ([@b3-ol-0-0-6736]). Although treating receptor tyrosine-protein kinase erb-2 (Her-2/neu/H2 N/HER2)-overexpressing gastric cancers with trastuzumab has significantly improved patient survival ([@b4-ol-0-0-6736]), the prognosis of patients with advanced gastric adenocarcinoma is poor; the 5-year survival rate is \<20% ([@b5-ol-0-0-6736]), which may in part be due to the lack of prognostic and diagnostic biomarkers. Molecular biomarker expression provides prognostic value and prompts the development of more effective molecular targeted drugs. Genetic and epigenetic alterations of proto-oncogenes and tumor-suppressor genes, including epidermal growth factor receptor and those involved in the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathway, have been associated with gastric cancer ([@b6-ol-0-0-6736],[@b7-ol-0-0-6736]).

The cyclin D protein family regulates cell cycle progression, which is mediated by their interactions with cyclin-dependent kinases 2, 4 and 6 ([@b8-ol-0-0-6736]). There have been three isoforms, cyclin D1 (CCND1); cyclin D2 (CCND2); and cyclin D3 (CCND3), identified in humans ([@b9-ol-0-0-6736],[@b10-ol-0-0-6736]). Overexpression of *CCND1* is correlated with tumor differentiation, poor survival and increased metastasis ([@b11-ol-0-0-6736]--[@b13-ol-0-0-6736]). Amplification of *CCND1* has been associated with non-small cell lung cancers ([@b14-ol-0-0-6736],[@b15-ol-0-0-6736]), head and neck squamous cell carcinomas ([@b16-ol-0-0-6736]--[@b18-ol-0-0-6736]) and pancreatic carcinomas ([@b19-ol-0-0-6736]). CCND1, CCND2 and CCND3 serve differential roles in tumor cell carcinogenesis that are cell and tissue-type specific ([@b20-ol-0-0-6736]). High levels of *CCND2* expression were observed in ovarian and testicular tumors ([@b21-ol-0-0-6736],[@b22-ol-0-0-6736]), and overexpression of *CCND2* has been associated with gastric cancer progression ([@b23-ol-0-0-6736],[@b24-ol-0-0-6736]). In addition, CCND3 has been associated with cell proliferation as well as induction and/or maintenance of terminal differentiation ([@b25-ol-0-0-6736]). Furthermore, overexpression of *CCND1* and *CCND3* has been identified in malignant melanomas ([@b26-ol-0-0-6736]), pancreatic cancer ([@b27-ol-0-0-6736]) and ductal carcinoma of the breast ([@b28-ol-0-0-6736]). To understand the contribution of CCND1, CCND2 and CCND3 to tumor progression, a detailed analysis of their expression levels in gastric cancer must be explored.

The aim of the present study was to evaluate the expression of CCND1 protein and its correlation with the clinical outcome of patients with gastric cancer. In order to identify the effects of CCND1, CCND2 and CCND3 in cancer cells, their differential roles in gastric cancer were examined. It was hypothesized that increased CCND1 expression may be used as biomarker in patients with gastric cancer. Therefore, data on *CCND1*, *CCND2* and *CCND3* mRNA expression were extracted from the Oncomine database ([@b29-ol-0-0-6736]) for gastric cancer, and the effect of *CCND1*, *CCND2* and *CCND3* expression level on overall survival (OS) and progression-free survival (PFS) was examined by Kaplan-Meier analysis.

Materials and methods
=====================

### Patients

Fresh specimens were collected from 32 patients with gastric adenocarcinoma who underwent radical resection at National Cheng Kung University Hospital (Tainan, Taiwan) between August 2003 and August 2008. The mean age was 60±11 years old (range, 35--82 years old; 20 males, 12 females). A total of 32 pairs of cancerous and matched adjacent normal gastric mucosa tissues were collected and analyzed as previously described ([@b30-ol-0-0-6736]). The Tumor, Node, Metastasis system by the American Joint Committee on Cancer was used for the classification, grading and staging of gastric cancer ([@b31-ol-0-0-6736]). The specimens were preserved in the Human Biobank within the Research Center of Clinical Medicine of the National Cheng Kung University Hospital (Tainan, Taiwan). All the patients provided written informed consent, and the study was approved by the Institutional Review Board of National Cheng Kung University Hospital (approval no., ER-97-148).

### Western blot analysis of CCND1 protein

Total cell lysates were prepared and analyzed by 10% SDS-PAGE as previously described ([@b30-ol-0-0-6736],[@b32-ol-0-0-6736],[@b33-ol-0-0-6736]). Membranes were blocked with 5% (w/v) skimmed milk (Merck KGaA, Darmstadt, Germany) for 1 h at room temperature and incubated with the following primary antibodies overnight at 4°C: Anti-CCND1 (cat. no., 2922; dilution, 1:2,000; Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-β-actin (cat. no., GTX26276; dilution, 1:5,000; GeneTex, Inc., Irvine, CA, USA). Membranes were then incubated for 1 h at room temperature with peroxidase-conjugated goat anti-rabbit IgG (cat. no. 7074S; 1:3,000; Cell Signaling Technology, Inc.) or peroxidase-conjugated sheep anti-mouse IgG antibody (ECL anti-mouse IgG; cat. no. NA931V; 1:3,000) (Amersham Pharmacia Biosciences, Buckinghamshire, U.K.). Immunodetection was performed using the horseradish peroxidase-based SuperSignal Chemiluminescent Substrate (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA). For quantification, the bands were measured with the AlphaImager 2200 Imaging System (Alpha Innotech; Bio-Techne, Minneapolis, MN, USA), and the densities of the CCND1 bands were normalized to those of the β-actin bands. CCND1 expression was quantified and described as a ratio to β-actin expression (CCND1/β-actin ratio).

### Bioinformatics and statistical analysis

A search of the Oncomine database (<http://www.oncomine.com>) ([@b34-ol-0-0-6736]) was initially conducted to systematically assess the expression level of the *CCND1*, *CCND2* and *CCND3* genes in gastric cancer. For this, normal vs. cancer tissues were compared in the differential analysis. The results were analyzed for their P-values, fold change and cancer subtype. The prognostic value of the *CCND1*, *CCND2* and *CCND3* genes in gastric cancer was also analyzed using the Kaplan-Meier Plotter (<http://kmplot.com/analysis/>), as described previously ([@b35-ol-0-0-6736]). The following settings were used for the analysis: 'Overall survival'; 'progression-free survival'; 'autoselect best cutoff'; 'censore at threshold all' (patients surviving over the selected threshold are censored instead of excluded); 'tumor stage all'; 'tumor stage T all'; 'tumor stage N all'; 'tumor stage M all'; 'grade all'; 'Lauren classification all' ([@b2-ol-0-0-6736]); 'differentiation all'; and 'moderate and poor differentiation'. Tumors were classified according to WHO histopathological type ([@b36-ol-0-0-6736]). Three cyclin D genes probe sets were available: 208712_at at *CCND1*, 200953_s\_at at *CCND2* and 201700_at at *CCND3*, and patients were split according to median expression or to expression at best cut-off for each probe. A total of 1,065 patients with gastric cancer were assessed using a Kaplan-Meier plot ([@b36-ol-0-0-6736]) and HER2 status was identified using the gene chip probe set 216836_s\_at, as previously described ([@b37-ol-0-0-6736]). The hazard ratio (HR) 95% confidence intervals and logrank P-values were calculated and described. P\<0.05 was considered to indicate a statistically significant difference. The data were extracted from the Oncomine database and Kaplan-Meier Plotter between March 2015 and August 2015. Finally, the association between CCND1 protein expression, assessed according to previously published protocols ([@b30-ol-0-0-6736],[@b38-ol-0-0-6736]) (CCND1/β-actin ratio), and differentiation type (moderate and poor differentiation) in fresh specimens derived from patients with gastric adenocarcinoma was assessed using the Student\'s t-test. The statistical differences between two groups were assessed, and P\<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

### Analysis of CCND1, CCND2 and CCND3 gene expression

Data for *CCND1*, *CCND2* and *CCND3* transcript expression were extracted from the Oncomine database for gastric cancer, focusing on cancer vs. normal patient datasets. The statistical significance, fold change, patient number, and type of tissues that displayed upregulation or downregulation of *CCND1, CCND2* and *CCND3* gene expression were also analyzed in normal vs. cancer tissues from the Oncomine database. The Derrico and Cho datasets obtained from Oncomine is embedded in the NCBI GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) at accession numbers GSE13911 and GSE13861, respectively ([Fig. 1](#f1-ol-0-0-6736){ref-type="fig"}). Overexpression and downregulation of the *CCND1, CCND2* and *CCND3* genes were identified in gastric cancer ([Fig. 1](#f1-ol-0-0-6736){ref-type="fig"}). To determine the clinical relevance of *CCND1*, *CCND2* and *CCND3* expression in human gastric cancer, their expression profiles in the oncomine cancer microarray database were analyzed. Information on the expression of *CCND1*, *CCND2* and *CCND3* in normal and cancerous gastric tissues was compiled from all of the microarray studies in the database ([@b39-ol-0-0-6736],[@b40-ol-0-0-6736]). The histological type of gastric adenocarcinoma was divided into intestinal, diffuse and mixed types ([@b2-ol-0-0-6736]). As demonstrated in [Fig. 1A](#f1-ol-0-0-6736){ref-type="fig"}, *CCND1* expression was significantly increased in gastric intestinal-type adenocarcinoma of gastric cancer ([@b40-ol-0-0-6736]). CCND2 expression was significantly increased in several types of gastric cancer, including diffuse gastric adenocarcinoma, gastric intestinal-type adenocarcinoma and gastric mixed adenocarcinoma ([Fig. 1B-E](#f1-ol-0-0-6736){ref-type="fig"}) ([@b39-ol-0-0-6736],[@b40-ol-0-0-6736]). By contrast, CCND3 expression was significantly decreased in gastric mixed adenocarcinoma ([Fig. 1F](#f1-ol-0-0-6736){ref-type="fig"}) ([@b39-ol-0-0-6736]). Oncomine analysis of neoplastic vs. normal tissue revealed that *CCND1* and *CCND2* were overexpressed in gastric cancer from the GSE13911 and GSE13861 datasets, respectively.

### Association of CCND1, CCND2 and CCND3 expression with OS and PFS in patients with gastric cancer

To analyze the association of *CCND1*, *CCND2* and *CCND3* expression with gastric cancer patient survival, Kaplan-Meier survival curves were constructed ([Fig. 2](#f2-ol-0-0-6736){ref-type="fig"}). A significant association was identified between *CCND1*, *CCND2* and *CCND3* mRNA and survival (P\<0.05, log-rank test). Overexpression of *CCND1* ([Fig. 2A and B](#f2-ol-0-0-6736){ref-type="fig"}) was correlated with lower OS and PFS. By contrast, *CCND2* overexpression was correlated with increased survival ([Fig. 2C and D](#f2-ol-0-0-6736){ref-type="fig"}). Overexpression of *CCND3* was correlated with lower OS and PFS ([Fig. 2E and F](#f2-ol-0-0-6736){ref-type="fig"}).

### Effect of CCND1, CCND2 and CCND3 expression on gastric cancer patient survival by differentiation types

When the analysis was restricted by differentiation type, significant differences in OS and PFS were observed for the expression of the *CCND1, CCND2* and *CCND3* genes in patients with moderately and poorly differentiated tumors. Specifically, high CCND1 expression was not associated with PFS compared with that of patients with low CCND1 expression in patients with moderately differentiated gastric cancer ([Fig. 3A](#f3-ol-0-0-6736){ref-type="fig"}), but in low CCND1 expression was significantly (P=0.0079) longer associated with PFS compared with that of patients with high CCND1 expression in patients with poorly differentiated tumors ([Fig. 3B](#f3-ol-0-0-6736){ref-type="fig"}). By contrast, high CCND2 expression was associated with a significantly poorer (P=0.032) PFS in patients with moderately differentiated tumors ([Fig. 3C](#f3-ol-0-0-6736){ref-type="fig"}), but not in those with poorly differentiated gastric cancer ([Fig. 3D](#f3-ol-0-0-6736){ref-type="fig"}). Additionally, low CCND3 expression was associated with significantly (P=0.039) longer PFS in patients with moderately differentiated tumors ([Fig. 3E](#f3-ol-0-0-6736){ref-type="fig"}), but not in patients with poorly differentiated gastric cancer ([Fig. 3F](#f3-ol-0-0-6736){ref-type="fig"}). The results demonstrated that the high expression of CCND1 was significantly correlated with poor differentiation and poor survival, while high expression of CCND2 and CCND3 was significantly correlated with moderate differentiation and poor survival.

### Association of CCND1, CCND2 and CCND3 expression with gastric cancer patient survival by HER2 status

HER2 overexpression has been correlated with poor outcomes and a more aggressive disease ([@b41-ol-0-0-6736]); however, the association between HER2 status and the prognosis of patients with gastric cancer remains controversial ([@b42-ol-0-0-6736]). To analyze the association of CCND1, CCND2 and CCND3 expression and HER2 status with survival, Kaplan-Meier PFS curves of PFS stratified by CCND1, CCND2 and CCND3 mRNA expression in HER2-negative and HER2-positive tumors were constructed. Overexpression of CCND1 ([Fig. 4A and B](#f4-ol-0-0-6736){ref-type="fig"}) was associated with reduced PFS in HER2-negative and HER2-positive tumors. By contrast, reduced CCND2 expression was associated with lower PFS in patients with either HER2-negative or HER2-positive tumors ([Fig. 4C and D](#f4-ol-0-0-6736){ref-type="fig"}). Overexpression of *CCND3* ([Fig. 4E and F](#f4-ol-0-0-6736){ref-type="fig"}) was associated with reduced PFS in HER2-negative and HER2-positive tumors. These results indicated that *CCND1*, *CCND2* and *CCND3* expression, and HER2 status were associated with survival.

### Effects of CCND1, CCND2 and CCND3 expression on the PFS of patients with poorly differentiated tumors by HER2 status

When the analysis was limited to those patients with gastric cancer with poorly differentiated tumors and was restricted by HER2 status, significant differences in PFS were observed between high and low expression levels of *CCND1*, *CCND2* and *CCND3* ([Fig. 5](#f5-ol-0-0-6736){ref-type="fig"}). Low *CCND1* expression was associated with significantly longer PFS in patients with poorly differentiated, HER2-negative tumors ([Fig. 5A](#f5-ol-0-0-6736){ref-type="fig"}), but not in those with poorly differentiated, HER2-positive tumors ([Fig. 5B](#f5-ol-0-0-6736){ref-type="fig"}). By contrast, low CCND2 expression was associated with significantly poorer PFS in patients with poorly differentiated, HER2-negative tumors ([Fig. 5C](#f5-ol-0-0-6736){ref-type="fig"}), but not in those with poorly differentiated, HER2-positive tumors ([Fig. 5D](#f5-ol-0-0-6736){ref-type="fig"}). PFS was not affected by CCND3 gene expression level in poorly differentiated, HER2-negative or HER2-positive tumors ([Fig. 5E and F](#f5-ol-0-0-6736){ref-type="fig"}, respectively). However, moderately differentiated tumors were not analyzed in the present study due to the small number of patients. Overexpression of CCND1 was significantly correlated with HER2-negative tumors, poor differentiation and poor survival. Additionally, downregulation of CCND2 was significantly correlated with poor differentiation, HER2-negative tumor status and poor survival. Taken together, these results suggest that overexpression of CCND1 is predictive of a poor prognosis and serves an important role in poorly differentiated, HER2-negative gastric tumors.

### CCND1 protein expression in clinical samples of gastric cancer tissues

CCND1 expression was also compared in moderately and poorly differentiated gastric cancer, and CCND1 protein expression was examined by western blot analysis in tumor and adjacent normal gastric tissues of 32 patients. All 32 cases of gastric cancer were adenocarcinomas, including 13 moderately differentiated and 19 poorly differentiated tumors ([Table I](#tI-ol-0-0-6736){ref-type="table"}). Analysis of the relative expression of CCND1 in moderately ([Fig. 6A](#f6-ol-0-0-6736){ref-type="fig"}) and poorly ([Fig. 6B](#f6-ol-0-0-6736){ref-type="fig"}) differentiated tissues indicated that the CCND1/β-actin ratio in poorly differentiated samples was significantly greater compared with that in moderately differentiated samples (P\<0.0018) ([Fig. 6C](#f6-ol-0-0-6736){ref-type="fig"}). In summary, the overexpression of CCND1 is associated with poorly differentiated gastric cancer.

Discussion
==========

Analysis of *CCND1, CCND2* and *CCND3* expression in human gastric cancer identified that overexpression of *CCND1* was associated with poor survival of patients with poorly differentiated gastric cancer. In addition, the effect of *CCND1* overexpression in patients with HER2-negative tumors was correlated with poor outcomes. The present study suggests that the overexpression of *CCND1*, but not of *CCND2* or *CCND3*, in poorly differentiated gastric cancer is closely associated with lower survival rates. CCND2 and CCND3 expression were associated with moderate differentiation. Consistent with these results, the present study identified that the CCND1 protein is overexpressed in poorly differentiated gastric tumors. Thus, CCND1 serves a prognostic role in tumor progression, and is involved in the regulation of tumor cell differentiation.

Oncomine analysis identified a strong correlation between *CCND1* and *CCND2* gene expression and certain subtypes of gastric cancer in the present study. Histologically, gastric cancer is divided into two types in the Lauren classification: Intestinal and diffuse ([@b2-ol-0-0-6736]). In the present study, gastric intestinal-type adenocarcinomas were associated with *CCND1* expression, while diffuse gastric adenocarcinoma, gastric intestinal-type adenocarcinoma and gastric mixed adenocarcinoma types were associated with *CCND2* expression. Notably, a previous study suggested that promoter hypermethylation of *CCND2* caused the loss of CCND2 function in gastric cell lines and primary gastric carcinomas ([@b43-ol-0-0-6736]). In addition, CCND2 protein expression was not detected in KATOIII, AGS, MKN45 or N87 cell lines ([@b43-ol-0-0-6736]). It has been suggested that hypermethylation of the *CCND2* promoter occurs in breast ([@b44-ol-0-0-6736]), prostate ([@b45-ol-0-0-6736]) and gastric cancer ([@b43-ol-0-0-6736]). To date, there have been few studies investigating *CCND2* promoter hypomethylation in colon cancer ([@b46-ol-0-0-6736]). These studies explain that CCND2 overexpression was an early event noted in colon polyps ([@b47-ol-0-0-6736]), and possibly the overexpression of CCND2, but not of CCND1 or CCND3, was associated with metastatic tumors ([@b46-ol-0-0-6736]). As patients with diffuse gastric cancer exhibit poorer prognoses and higher incidences of metastasis compared with those of patients with intestinal type tumors ([@b48-ol-0-0-6736],[@b49-ol-0-0-6736]), it is possible that CCND2 overexpression in diffuse gastric adenocarcinoma is also associated with promoter hypomethylation in the early stage, and reveals a potential metastatic role for CCND2.

The Kaplan-Meier analysis of the present study identified correlations between *CCND1, CCND2* and *CCND3* gene expression and clinical outcomes. An elevated expression of *CCND1* was significantly associated with poor differentiation and poorer PFS. Clinically, the major histological types of metastatic gastric cancer include poorly differentiated and signet ring adenocarcinomas ([@b50-ol-0-0-6736],[@b51-ol-0-0-6736]). *CCND1* overexpression is associated with shorter patient survival in mantle cell lymphoma and head and neck squamous cell carcinoma ([@b11-ol-0-0-6736],[@b12-ol-0-0-6736]). In addition, *CCND1* overexpression is often associated with increased metastasis, which is consistent with the ability of *CCND1* to enhance migration and invasion ([@b12-ol-0-0-6736],[@b52-ol-0-0-6736]). The expression and potential roles of *CCND1* in gastric cancer have been investigated, and previous studies have demonstrated the manner in which it contributes to carcinogenesis ([@b53-ol-0-0-6736]--[@b58-ol-0-0-6736]). For example, direct evidence that CCND1 serves an essential role in the cell proliferation of gastric cancer cell lines has been presented ([@b54-ol-0-0-6736]). Evidence has also demonstrated that increased *CCND1* expression was associated with decreased OS in patients with resected gastric adenocarcinoma ([@b59-ol-0-0-6736]).

The majority of tumor markers are produced at much higher levels in cancer cells than in normal cells, and may be identified in the blood, urine or tumor tissues of patients with cancer ([@b60-ol-0-0-6736]--[@b62-ol-0-0-6736]). Thus, tumor marker analysis may reflect the various stages of the cancer and may assist clinicians in the planning and monitoring of cancer treatment. The present study attempted to identify CCND1 as a prognostic biomarker of poorly differentiated gastric cancer. In a previous study, inhibition of CCND1 using specific targeting was presented as a novel gastric cancer therapy ([@b56-ol-0-0-6736]). Amplification of CCND1 causes resistance to certain cytotoxic drugs and targeted therapies, including gefitinib and tamoxifen ([@b63-ol-0-0-6736],[@b64-ol-0-0-6736]), and is a potential predictor of resistance to cancer therapy in breast cancer ([@b65-ol-0-0-6736]). In addition, *HER2* is overexpressed and/or gene-amplified in gastric cancer, although numerous studies have yielded inconsistent data regarding the prognostic relevance of HER2 ([@b66-ol-0-0-6736]). Whereas certain studies demonstrated that HER2 positivity was associated with significantly poor prognosis ([@b66-ol-0-0-6736]), other studies identified no association between HER2 status and prognosis ([@b66-ol-0-0-6736]). In a previous study, 7--17% of patients with gastric cancer were HER2-positive and, thus, suitable candidates for trastuzumab therapy ([@b67-ol-0-0-6736]). In addition, amplification of CCND1 was revealed in 17.4% of gastric cancers ([@b60-ol-0-0-6736]). Clinically, intra-tumor heterogeneity often results in failure of gene therapy and targeted therapy in gastric adenocarcinoma ([@b60-ol-0-0-6736]). In the present study, the heterogeneity of the potential target genes, *CCND1*, *CCND2* and *CCND3*, was systematically analyzed. To identify the most prevalent molecular targets in poorly differentiated gastric cancer, the patient outcomes relative to CCND1 overexpression and HER2 status were determined. The results imply that CCND1 overexpression of poorly differentiated gastric cancer causes resistance to certain cytotoxic drugs and targeted therapies.

In conclusion, to the best of our knowledge, the present study is the first to suggest that overexpression of CCND1 protein is correlated with lower PFS in poorly differentiated gastric cancer. These results demonstrate that CCND1, but not CCND2 or CCND3, is overexpressed in human gastric carcinoma, and that the expression of this protein is correlated with tumor differentiation. Thus, CCND1 expression is a valuable prognostic indicator for gastric cancer.

The present study was supported by grants from the Ministry of Science and Technology of Taiwan (grant nos. MOST 102-2311-B041-001 and MOST 103-2311-B-041-001). The authors would like to thank the Human Biobank, the Research Center of Clinical Medicine and the National Cheng Kung University Hospital for their support.

![Gene expression of *CCND1, CCND2* and *CCND3* from Oncomine database in gastric cancer. *CCND1* was overexpressed in the Derrico dataset. *CCND2* was overexpressed in the Derrico and Cho datasets. *CCND3* was underexpressed in the Cho dataset. The expression patterns of (A) *CCND1*, (B-E) *CCND2* and (F) *CCND3* in gastric cancer datasets were obtained from the Oncomine database. (A and B) 1, gastric mucosa; 2, gastric intestinal type adenocarcinoma. (C) 1, gastric tissue; 2, diffuse gastric adenocarcinoma. (D) 1, gastric tissue; 2, gastric intestinal type adenocarcinoma. (E and F) 1, gastric tissue; 2, gastric mixed adenocarcinoma. *CCND, cyclin D*.](ol-14-04-4517-g00){#f1-ol-0-0-6736}

![Kaplan-Meier survival curves regarding *CCND1, CCND2* and *CCND3* gene expression in patients with gastric cancer. High expression of *CCND1* was associated with lower OS (A) and PFS (B). Low expression of *CCND2* was correlated with lower OS (C) and PFS (D). High expression of *CCND3* was correlated with lower OS (E) and PFS (F). The total number of patients in the low- and high-expression groups, as well as the HR and P-values (log-rank), are included. *CCND*, cyclin D; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.](ol-14-04-4517-g01){#f2-ol-0-0-6736}

![Progression-free survival of patients with moderately and poorly differentiated gastric cancers by *CCND1, CCND2* and *CCND3* gene expression. CCND1 expression was associated with PFS in patients with moderately (A) and poorly (B) differentiated gastric cancer. CCND2 expression was associated with PFS in patients with moderately (C) and poorly (D) differentiated gastric cancer. CCND3 expression was associated with PFS in patients with moderately (E) and poorly (F) differentiated gastric cancer. The total number of patients in the low- and high-expression groups, as well as the HR and P-values (log-rank), are included. *CCND*, cyclin D; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.](ol-14-04-4517-g02){#f3-ol-0-0-6736}

![Progression-free survival of patients with gastric cancer with by HER2 status, and CCND1, *CCND2* and *CCND3* gene expression. Progression-free survival of patients with (A, C and E) HER2-negative or (B, D and F) HER2-positive tumors by (A and B) *CCND1*, (C and D) *CCND2* and (E and F) *CCND3* expression. The total number of patients in the low- and high-expression groups, as well as the HR and P-values (logrank), are included. *CCND, cyclin D*; HR, hazard ratio; HER2, receptor tyrosine-protein kinase erb-2.](ol-14-04-4517-g03){#f4-ol-0-0-6736}

![Progression-free survival of patients with poorly differentiated gastric cancer by HER2 expression, and *CCND1, CCND2* and *CCND3* gene expression. Progression-free survival of patients with (A, C and E) poorly differentiated, HER2-negative or (B, D and F) poorly differentiated, HER2-positive gastric cancer by (A and B) *CCND1*, (C and D) *CCND2* and (E and F) *CCND3* expression. The total number of patients in the low- and high-expression groups, as well as the HR and P-values (logrank), are included. *CCND, cyclin D*; HR, hazard ratio; HER2, receptor tyrosine-protein kinase erb-2.](ol-14-04-4517-g04){#f5-ol-0-0-6736}

![Correlation between differentiation type and CCND1 protein expression in gastric cancer. The tumor/normal ratio of CCND1 expression (the ratio of CCND1 expression in specimens from gastric cancer relative to that in corresponding normal gastric tissues) was determined by western blot analysis. CCND1 expression is presented relative to that of β-actin (CCND1/β-actin ratio). (A) CCND1 expression was measured in moderately differentiated tumors from gastric cancer and normal stomach tissues. (B) CCND1 expression was measured in specimens of poorly differentiated gastric cancer and normal stomach tissues. (C) The CCND1/β-actin ratio of 32 samples was compared with that from moderately and poorly differentiated tumors (P=0.0018). N, normal tissue; T, gastric cancer tissue; CCND1, cyclin D1.](ol-14-04-4517-g05){#f6-ol-0-0-6736}

###### 

Demographics and histopathological data of patients with gastric cancer.

  Characteristic                                                   No. of patients (%)
  ---------------------------------------------------------------- ---------------------
  Patients with gastric cancer                                     32 (100)
  Mean age ± standard deviation, years                             60±11
  Sex                                                              
    Male                                                           20 (62)
    Female                                                         12 (38)
  Histological differentiation                                     
    Moderate                                                       13 (40)
    Poor                                                           19 (60)
  Lauren\'s classification                                         
    Intestinal                                                     15 (47)
    Diffuse                                                        12 (37)
    Mixed                                                          5 (16)
  American Joint Committee on cancer tumor node metastasis stage   
    I                                                              7 (22)
    II                                                             9 (28)
    III                                                            12 (38)
    IV                                                             4 (12)

[^1]: Contributed equally
